Home Cancer AstraZeneca Immunology Drug Cuts Lung Cancer Deaths by Nearly 33%

AstraZeneca Immunology Drug Cuts Lung Cancer Deaths by Nearly 33%

192
0

As reported in Reuters, Ben Hircschler writes that AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.